TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28399551
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for degenerative spondylolisthesis (DS) including instrumented fusion (72%), noninstrumented fusion (21%), and decompression alone (7%).
Study: 25460264
Drug: Baseline standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline standard inpatient treatment
Study: 23480783
Drug: Metformin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (n = 24)
Study: 23480783
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus Simvastatin (n = 18)
Study: 18957487
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 or 6 mg/kg) plus methotrexate (MTX)
Study: 16763547
Drug: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone (0.16 mg/kg, subcutaneous injection, 3 cycles of 10 days over 3 months)
Study: 16763547
Drug: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
Study: 15123028
Drug: Intravenous diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous diazepam 0.2 mg/kg
Study: 11304782
Drug: Intravenous fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fluorouracil plus leucovorin (5‐FU/LV)
Study: 8306013
Drug: Oxytocin plus
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin plus ergometrine (Syntometrine: 5 units of oxytocin with 0.5 mg of ergometrine)
Study: 3521532
Drug: Haloperidol (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (n = 21), mean dose 7.24 mg, 4 to 16 mg range
Study: 3521532
Drug: Amitriptyline (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (n = 20), mean dose 147.62 mg, 100 to 175 mg range
Study: 26700937
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of atorvastatin once daily for 2 years
Study: 26700937
Drug: Identical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo once daily for 2 years
Study: 22936298
Drug: Polyether (PE:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyether (PE: Impregum Penta H/L DuoSoft Quick, 3 M ESPE) with manufacturer's recommended working time
Study: 17006324
Drug: CsA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA plus atorvastatin
Study: 17006324
Drug: TRL plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRL plus atorvastatin
Study: 3532602
Drug: Heat-stable 17D
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable 17D yellow fever vaccine
Study: 3532602
Drug: Non-stabilized yellow
Normalized name: yellow OB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-stabilized yellow fever vaccine
Study: 24606601
Drug: Self-management group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-management group intervention (eight weekly sessions, 90 minutes each)
Study: 9438888
Drug: Popliteal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Popliteal block (30 ml of alkalinized 3% chloroprocaine) and posterior cutaneous nerve of the thigh block (10 ml of 1% lidocaine)
Study: 9438888
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (65 mg of 5% hyperbaric lidocaine)
Study: 8235870
Drug: Extension treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extension treatment
Study: 8235870
Drug: Flexion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexion treatment
Study: 8235870
Drug: Placebo-control treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-control treatment
Study: 3680597
Drug: 4-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-g dose of mezlocillin
Study: 3680597
Drug: 5-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-g dose of mezlocillin
Study: 20197582
Drug: Antithrombotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithrombotic therapy (including antiplatelet and antithrombin agents)
Study: 15739719
Drug: Daily 15‐minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 15‐minute oral stimulation program for 10 days before the start of oral feedings
Study: 15739719
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral stimulation program)
Study: 14969216
Drug: Immediate non-occlusal
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate non-occlusal loading of dental implants
Study: 8635262
Drug: LDL-apheresis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis plus medication (simvastatin 40 mg/day)
Study: 8635262
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (simvastatin 40 mg/day)
Study: 8635262
Drug: LDL-apheresis plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-apheresis plus medication
Study: 21556784
Drug: Telephonic quitline
Normalized name: quinoline yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephonic quitline intervention (counseling and nicotine replacement therapy)
Study: 19382469
Drug: Integrative medical
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative medical regimen (IMR) - Jiangya Capsule (JYC) and Nimodipine (ND)
Study: 12365016
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with mitomycin C (6 mg/m(2) i.v.) and 5‐fluorouracil (310 mg/m(2) i.v.) for 5 consecutive days during postoperative Weeks 1 and 3, followed by 5‐FU (100 mg/m(2) orally) daily from postoperative Week 5 until disease recurrence.
Study: 12365016
Drug: Postoperative adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adjuvant chemotherapy with mitomycin C and 5‐fluorouracil.
Study: 7648285
Drug: Zidovudine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (200 mg every 8 h for 3 days)
Study: 7648285
Drug: Didanosine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine (200 mg every 12 h for 3 days)
Study: 2649867
Drug: Oxytetracycline, Doxycycline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytetracycline, Doxycycline, Rifampin (oral monotherapy)
Study: 2649867
Drug: TMP/SMX (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP/SMX (oral monotherapy)
Study: 2649867
Drug: Rifampin plus
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin plus Oxytetracycline (combined oral therapy)
Study: 2649867
Drug: Rifampin plus
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin plus TMP/SMX (combined oral therapy)
Study: 2649867
Drug: Oxytetracycline plus
Normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytetracycline plus TMP/SMX (combined oral therapy)
Study: 2649867
Drug: Oral monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monotherapy combined with Streptomycin
Study: 2649867
Drug: Oral monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral monotherapy combined with Gentamicin
Study: 24825404
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (220 mg/d)
Study: 15083598
Drug: Intravenous glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycoprotein IIb/IIIa inhibitors
Study: 23745947
Drug: Crushed morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed morphine sulfate controlled-release (CR) tablets
Study: 23745947
Drug: Crushed morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed morphine sulfate and naltrexone hydrochloride extended-release capsules (MSN)
Study: 14618043
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day MgSO(4) infusion in 100 mL 0.9 NaCl solution (25 mL/hr) for 4 days after surgery
Study: 14618043
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL 0.9 NaCl solution (25 mL/hr)
Study: 14618043
Drug: MgSO(4) infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MgSO(4) infusion
Study: 11051622
Drug: Pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 200 mg bd for 7 days
Study: 11051622
Drug: Pivmecillinam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam 200 mg bd for 3 days
Study: 11051622
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg bd for 3 days
Study: 3160915
Drug: Ketanserin, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin, 40 mg
Study: 3160915
Drug: Ketoconazole, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole, 400 mg
Study: 27823876
Drug: 0.2 mL
Normalized name: isopropyl alcohol 0.2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL intranasal midazolam
Study: 27823876
Drug: 0.5 mL
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL intranasal midazolam
Study: 27823876
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL intranasal midazolam
Study: 25946554
Drug: Adalimumab (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (40 mg every 2 weeks after a loading dose)
Study: 25946554
Drug: Methotrexate (7.5-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (7.5-25 mg/wk)
Study: 23394621
Drug: Ceftizoxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime administered pre-incision
Study: 23394621
Drug: Ceftizoxime administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftizoxime administered post-clamping of the umbilical cord
Study: 19814948
Drug: Increased-dose selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased-dose selective serotonin reuptake inhibitor (SSRI)
Study: 19814948
Drug: Medication optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication optimization with SSRI plus clonazepam
Study: 10806822
Drug: Intravaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal misoprostol (100 mg)
Study: 28438471
Drug: Actovegin treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin treatment
Study: 25523883
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (500 mg, twice daily for 8 weeks)
Study: 21333021
Drug: FITNET (web-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: FITNET (web-based cognitive behavioural therapy)
Study: 9053465
Drug: Low-dose filgrastim
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose filgrastim (50 microg/m2)
Study: 29681235
Drug: Melatonin niosomes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin niosomes (MN) gel, 2.5 mg, 5 mg, and 10 mg, topically applied
Study: 29681235
Drug: Melatonin gel
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin gel (control)
Study: 26621513
Drug: Computerised cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerised cognitive behaviour therapy (cCBT)
Study: 11257563
Drug: Low-dose group
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose group (LDG): 2 mg/kg BN 52021, administered intravenously 120 mg BN 52021 before reperfusion.
Study: 11257563
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (HDG): 10 mg/kg BN 52021, administered intravenously 600 mg BN 52021 before reperfusion.
Study: 11257563
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG): Placebo administered before reperfusion.
Study: 7506166
Drug: nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide 200 mg/day
Study: 7506166
Drug: ketoprofen 150
Normalized name: ketoprofen 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketoprofen 150 mg/day
Study: 2872807
Drug: Terazosin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terazosin plus diuretic
Study: 2872807
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus diuretic
Study: 24086334
Drug: Azithromycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (30 mg/kg single dose)
Study: 22185601
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with heterologous vaccine (HE)
Study: 22185601
Drug: Vaccinated with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccinated with homologous inactivated vaccine (HO)
Study: 18337638
Drug: Caffeine (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.75 mg/kg) 3 times daily for 4 consecutive weeks
Study: 9152821
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine dry powder spray at dressing changes
Study: 9152821
Drug: No povidone
Normalized name: Povidone
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No povidone iodine spray (control group)
Study: 26088909
Drug: Intensive control
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive control (target BG range of 4.5‐6.0 mmol/L)
Study: 26088909
Drug: Conventional control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional control (target BG <10 mmol/L)
Study: 21525248
Drug: 2.5 g
Normalized name: Vaporizer 2.5 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 g L-leucine with each main meal (7.5 g/d)
Study: 19220847
Drug: Nanocrystalline hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocrystalline hydroxyapatite silica gel (Group 1, 3 months healing)
Study: 19220847
Drug: Nanocrystalline hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanocrystalline hydroxyapatite silica gel (Group 2, 6 months healing)
Study: 12682468
Drug: Ibutilide 0.008
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide 0.008 mg/kg body weight over 10 mins; if needed, amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Study: 12682468
Drug: Amiodarone 5
Normalized name: amiodarone 50 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone 5 mg/kg over 30 mins and 15 mg/kg over 24 hrs
Study: 10937764
Drug: Iodixanol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodixanol (320 mg I/ml)
Study: 11104872
Drug: Ioxaglate (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ioxaglate (320 mg I/ml)
Study: 8613058
Drug: UDCA (13-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (13-15 mg.kg-1.day-1)
Study: 1446728
Drug: GM-CSF plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM-CSF plus AraC (20 mg/m2/d s.c.)
Study: 3001664
Drug: ACTH 4-9
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-9 analog (5 mg)
Study: 3001664
Drug: ACTH 4-9
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-9 analog (10 mg)
Study: 3001664
Drug: ACTH 4-9
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-9 analog (20 mg)
Study: 11923794
Drug: Bivalirudin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin 1.0 mg/kg bolus followed by a 4-hour infusion at 2.5 mg/kg/h
Study: 11923794
Drug: Bivalirudin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin 0.75 mg/kg bolus followed by a 4-hour infusion at 1.75 mg/kg
Study: 11923794
Drug: Heparin 60
Normalized name: Heparine
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin 60 U/kg bolus
Study: 11923794
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (including bivalirudin and heparin) with eptifibatide
Study: 11923794
Drug: Bivalirudin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin and Heparin
Study: 26762374
Drug: Plant stanol
Normalized name: plant stanol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant stanol enriched soy-based yogurts (4.0 g plant stanols/d)
Study: 23180952
Drug: Probiotics (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to triple therapy
Study: 23180952
Drug: Probiotics (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks after triple therapy
Study: 23180952
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, and amoxicillin 1000 mg bid)
Study: 23180952
Drug: Probiotics (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (3 × 10(7)Lactobacillus acidophilus per day) for two weeks prior to or after triple therapy
Study: 19925528
Drug: Cilnidipine 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilnidipine 10-20 mg once daily for 4 weeks
Study: 19925528
Drug: Losartan 50-100
Normalized name: losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50-100 mg once daily for 4 weeks
Study: 28025969
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (valsartan tablet)
Study: 28025969
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (valsartan tablet)
Study: 11140029
Drug: Competency-based primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Competency-based primary care drug therapy (PCDT) training programme
Study: 3325318
Drug: Sustained-release theophylline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release theophylline capsules
Study: 3325318
Drug: Standard slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard slow-release theophylline tablets
Study: 27714649
Drug: Telephone-delivered stepped
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Telephone-delivered stepped collaborative care (CC)
Study: 23232039
Drug: Tobramycin nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI eFlow(®) rapid nebuliser
Study: 23232039
Drug: Tobramycin nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin nebuliser solution 300 mg/4 mL (TNS4) via PARI LC Plus(®) nebuliser
Study: 23232039
Drug: Tobramycin nebuliser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin nebuliser solution 300 mg/4 mL (TNS4)
Study: 21383098
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 150 mg maraviroc b.i.d. with darunavir-ritonavir
Study: 21383098
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 300 mg maraviroc b.i.d. with etravirine
Study: 21383098
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 150 mg maraviroc b.i.d. with etravirine-darunavir-ritonavir
Study: 11217680
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or reference drugs
Study: 9051392
Drug: Training plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training plus BCAA supplement
Study: 9051392
Drug: Sedentary plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedentary plus BCAA supplement
Study: 8364776
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) 300 mg 1 hour before each meal and at bedtime (n = 16)
Study: 8364776
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg bid (n = 12)
Study: 8364776
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg b.i.d.) plus metronidazole (250 mg t.i.d; n = 14)
Study: 29195025
Drug: CLM +
Normalized name: Chlorpheniramine
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLM + BUD (clarithromycin 0.25 g/d and budesonide 256 μg/d)
Study: 29195025
Drug: BUD (budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD (budesonide 256 μg/d)
Study: 18241260
Drug: DHA 5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA 5.4 g daily (n = 21)
Study: 15931018
Drug: Relaxation Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Relaxation Response (RR) intervention for 15 weeks, practicing techniques at home twice a day
Study: 3558936
Drug: Heparin-bonded pulmonary-artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded pulmonary-artery catheters
Study: 3558936
Drug: Non-heparin-bonded pulmonary-artery
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-heparin-bonded pulmonary-artery catheters
Study: 31708063
Drug: Star rating-targeted
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Star rating-targeted medications (oral antidiabetic medications, RAS antagonists, statins)
Study: 31708063
Drug: Nontargeted antihypertensive
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontargeted antihypertensive and antihyperlipidemic medications
Study: 25559252
Drug: Discontinued-incentive condition
Normalized name: Entex HC Discontinued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinued-incentive condition receiving weekly incentives during fall semester 2011, and no incentives during spring semester 2012
Study: 25559252
Drug: Continued-incentive condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued-incentive condition receiving weekly incentives during fall semester, and incentives on a variable-interval schedule during spring semester